The latest price target for United Therapeutics (NASDAQ:UTHR) was reported by B of A Securities on July 10, 2026. The analyst firm set a price target for $613.00 expecting UTHR to rise to within 12 months (a possible 14.44% upside). 35 analyst firms have reported ratings in the last year.

The latest analyst rating for United Therapeutics (NASDAQ:UTHR) was provided by B of A Securities, and United Therapeutics maintained their neutral rating.

The last upgrade for United Therapeutics Corp happened on May 7, 2026 when Wells Fargo raised their price target to $738. Wells Fargo previously had an equal-weight for United Therapeutics Corp.

The last downgrade for United Therapeutics Corp happened on April 25, 2025 when Wells Fargo changed their price target from $395 to $314 for United Therapeutics Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United Therapeutics was filed on July 10, 2026 so you should expect the next rating to be made available sometime around July 10, 2027.

While ratings are subjective and will change, the latest United Therapeutics (UTHR) rating was a maintained with a price target of $620.00 to $613.00. The current price United Therapeutics (UTHR) is trading at is $535.67, which is out of the analyst’s predicted range.